| 查看: 2843 | 回复: 7 | |||
[交流]
【求助】发（（很多金币））求一个新药的信息
|
|
商品名： Mepact 通用名：米伐木肽(mifamurtide) 分子式： C59H109N6O19P CAS登记号：83461-56-7 2009年获欧盟批准上市 求：此化合物的 1.理化性质 2.制剂、处方、工艺及分析检测 3.药理、毒性、药代 有来源出处更好，能有多少就给多少信息， 已有的就可以了，结束，谢谢回复 [ Last edited by wo668668 on 2011-1-2 at 23:52 ] |
回复此楼» 猜你喜欢
人工智能赋能聚合物及复合材料模型应用与实践
已经有0人回复
-
各国和国际组织现行药典注射用水质量标准
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有149人回复
-
求助用微谱数据库查询
已经有0人回复
-
计算化学与人工智能驱动的MOFs性能预测与筛选技术
已经有0人回复
-
研三实验求指导
已经有0人回复
-
金属材料多尺度计算模拟技术与应用：微观机理到宏观性能的集成工作
已经有0人回复
-
江西科技师范大学07生物学和08生物与医药大量调剂
已经有26人回复
-
【招聘】清北（济南）生物科技招聘AI制药研发计算人才
已经有18人回复
-
100701药学专业招调剂，5个名额，药物化学专业，主要是天然药物化学方向加药理
已经有4人回复
» 本主题相关商家推荐: (我也要在这里推广)
» 本主题相关价值贴推荐，对您同样有帮助:
- 【原创】多个1类临床前新药寻求合作和转让（DPP4,GLP-1,替尼类临床前新结构）
已经有26人回复
- 【求助】求助一个化合物的合成方法
已经有4人回复
- 【求助】20枚金币求助一个药品的销售额
已经有23人回复
- 【求助】新药立项信息查询如何操作
已经有10人回复
- 【求助】一个刚入手工艺员的疑惑
已经有17人回复
- 【求助】一个缓释片在体内达到哪些药动学参数才能算12h缓释？
已经有5人回复
- 【求助】关于一个药品发补延期的问题
已经有7人回复
» 抢金币啦！回帖就可以得到:
-
招收硕士研究生
+5/541
-
2026年山东科技大学低碳能源化工实验室招收化工工艺、环境工程硕士调剂信息
+1/181
-
南方科技大学纳米-飞秒-超快动力学课题组---诚聘博士后/助理研究员
+1/179
-
物理学调剂
+1/91
-
江苏大学，环境科学/环境工程专业，调剂
+1/86
-
齐鲁工业大学招收轻工、材料、化工、环境类研究生
+1/83
-
安徽省大别山中医药研究院 接收中药调剂生（中药、药学等10开头代码均可）
+1/77
-
重庆工商大学 教育部研究中心招收化工/环境/材料/石油/机械方向2026年调剂研究生
+1/53
-
大连大学-六盘水师范学院联合培养研究生接收调剂
+2/52
-
喀什大学环境生态修复功能材料与技术团队接收2026年调剂研究生
+1/43
-
五邑大学招收大量药学、生物与医药调剂生
+1/39
-
2026-大连大学～六盘水师范学院联合培养硕士研究生，招收化学、环境等相关专业
+1/38
-
考研调剂招生
+1/24
-
招收环境工程/化学工程/材料化工专业的调剂生4-5名。
+1/18
-
中科大科学岛分院2026年工程博士申请考核制-博士招生，4月10日截止
+1/11
-
河南理工大学化学化工学院招生材料、化工等相关专业调剂研究生
+1/10
-
福建理工大学招收专业代码08开头学术型硕士研究生
+1/5
-
中国石油大学（北京）招收油藏数值模拟、油气人工智能、油田化学等相关方向博士后
+1/5
-
招收【★计算化学、AI药物设计★】方向的硕士研究生（代码：1055/1007/0703）
+1/3
-
河南城建学院市政与环境工程学院2026年硕士研究生接收调剂公告
+1/1
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:37
wo668668(金币+10): 2010-12-31 12:52:08
warlen(金币+1):谢谢参与 2010-12-31 09:40:37
wo668668(金币+10): 2010-12-31 12:52:08
|
Systematic (IUPAC) name 2-[(N-{(2R)-[(2-acetamido-2,3-dideoxy-D-glucopyranos-3-yl)oxy]-propanoyl}-L-alanyl-D-isoglutaminyl-L-alanyl)amino]ethyl (2R)-2,3-bis(hexadecanoyloxy)propyl hydrogen phosphate Identifiers CAS number （1）83461-56-7 （2）838853-48-8 (mifamurtide sodium · xH2O) Chemical data Formula C59H109N6O19P Mol. mass 1237.499 g/mol SMILES eMolecules & PubChem Pharmacokinetic data Bioavailability N/A Half-life minutes (in plasma) 18 hrs (terminal) Therapeutic considerations Licence data EMA:Link Pregnancy cat. not investigated Legal status ℞ Prescription only Routes intravenous liposomal infusion over one hour muramylNAc-Ala-isoGln-Lys-tripeptide-PE Pharmacological Action Adjuvants, Immunologic [Link to MeSH] - Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The ... [show more] Adjuvants, Immunologic [Link to MeSH] - Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. [show less] Immunologic Factors [Link to MeSH] - Biologically active substances whose activities affect or play a role in the functioning of the immune system. Pharmacological Classification Chemical Actions and Uses [Link to MeSH] Pharmacologic Actions [Link to MeSH] Physiological Effects of Drugs [Link to MeSH] Immunologic Factors [Link to MeSH] Adjuvants, Immunologic [Link to MeSH] |
2楼2010-12-31 03:22:36
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:42
wo668668(金币+10): 2010-12-31 12:49:24
warlen(金币+1):谢谢参与 2010-12-31 09:40:42
wo668668(金币+10): 2010-12-31 12:49:24
|
可以参考一下wiki百科 http://en.wikipedia.org/wiki/Mifamurtide |
3楼2010-12-31 08:54:24
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:49
wo668668(金币+5): 2010-12-31 12:48:10
warlen(金币+1):谢谢参与 2010-12-31 09:40:49
wo668668(金币+5): 2010-12-31 12:48:10
|
欧洲批准米伐木肽(mifamurtide)注射剂上市 欧洲批准IDM Pharma公司的米伐木肽注射剂（mifamurtide，L-MTP-PE，:Mepact）上市，用于治疗非转移性可切除的骨肉瘤（少见但主要造成儿童和青年死亡的骨瘤）。本品是20余年来首个获准上市治疗骨肉瘤的新药。本品可在欧盟27个成员国以及冰岛、列支敦士登和挪威销售。 米伐木肽是20余年来首个改善骨肉瘤患者长期存活的药品。患者术前化疗，随后手术切除骨瘤，而后再化疗。当患者接受术后化疗的同时也静脉注射注射本品免疫治疗（一周2次，3个月，随后一周1次，6个月）。化疗如同炸弹摧毁肿瘤，而米伐木肽如同魔铲可彻底清除疾病显微战壕内的残留物。 米伐木肽通过刺激诸如巨噬细胞等某些白细胞来杀灭肿瘤细胞。本品制成球形脂质体，囊泡内是胞壁酰三肽（MTP）。此脂质触发巨噬细胞去消耗米伐木肽。一旦消耗完，MTP刺激尤其是在肝、脾和肺内的巨噬细胞去寻找肿瘤并杀灭之。 米伐木肽注射剂获准上市基于Ⅲ期临床研究结果。国立癌症研究所（NCI）建立的协作组，由儿童肿瘤组（COG）进行研究，完成本品治疗骨肉瘤最大研究课题在册的患者约800例。研究评价了米伐木肽与3～4种辅助化疗药（顺铂、多柔比星、甲氨蝶呤、有或无异环磷酰胺）联合用药的结果。研究显示，米伐木肽与化学药物联合使用可使死亡率降低约30%，78&经治疗的患者存活长达6年以上。 |
4楼2010-12-31 08:57:54
★
warlen(金币+1):谢谢参与 2010-12-31 09:40:55
wo668668(金币+5): 2010-12-31 12:52:37
warlen(金币+1):谢谢参与 2010-12-31 09:40:55
wo668668(金币+5): 2010-12-31 12:52:37
|
毒理学：急性毒性数据库 http://www.cerc.usgs.gov/data/acute/acute.html 化合物毒性相关数据库 Toxnet http://toxnet.nlm.nih.gov/ 化学药物数据库：化学数据库 NIST的Chemistry WebBook http://webbook.nist.gov/chemistry/ 它是美国国家标准与技术研究院NIST的基于Web的物性数据库，Chemistry WebBook可以看作是NIST的标准参考数据库Standard Reference Data中一部分与化学有关的数据库的Web版本，可通过分子式检索、化学名检索、CAS 登录号检索、离子能检索、电子亲和力检索、质子亲和力检索、酸度检索、表面活化能检索、振动能检索、电子能级别检索、结构检索、分子量检索和作者检索等方法，得到气相热化学数据、浓缩相热化学数据、相变数据、反应热化学数据、气相离子能数据、离子聚合数据、气相IR色谱、质谱、UV/Vis色谱、振动及电子色谱等。 |
5楼2010-12-31 09:05:28
6楼2010-12-31 09:12:02
★
小木虫(金币+0.5):给个红包，谢谢回帖交流
wo668668(金币+5): 2011-01-02 23:53:03
小木虫(金币+0.5):给个红包，谢谢回帖交流
wo668668(金币+5): 2011-01-02 23:53:03
|
Information Generic Name: mifamurtide Trade Name: Mepact (EU), Junovan (US) Synonym: MTP-PE, muramyl tripeptide phosphatidylethanol Entry Type: New chemical entity Category BNF Category: Other antineoplastic drugs (08.01.05) Pharmacology: Liposomal formulation of muramyl tripeptide phosphatidylethanolamine Epidemiology: Osteosarcoma is a rare disease, with about 1,200 new cases in Europe each year (12). 2-3% of all childhood cancers are osteosarcoma with survival at 60-65% (11) Indication: Osteosarcoma Additional Details: non-metastatic, resectable Developmental Status UK: Launched EU: Launched US: Pre-registration (Filed) UK launch Plans: Available only to registered users Actual UK launch date: 01/02/2010 Method(s) of Administration Intravenous Comments Feb 10: Launched in EU [13]. 06/02/2010 16:58:41 Jun 09: Takeda have taken over the originator company (May 09). EU launch delayed until 2010 (personal communication). 19/06/2009 12:15:04 Mar 09: Company plan to submit an amended NDA to FDA mid-2009 after receiving a non-approvable letter, requesting more data, in Aug 08 (10) 09/03/2009 19:35:10 Mar 09: Licensed in EU (10) 09/03/2009 19:21:55 EU CHMP positive opinion for the treatment of patients with non-metastatic, resectable osteosarcoma, Nov 08. Recommendation to be adopted in Dec 08, with final approval 60-90days later. (9) 21/11/2008 09:35:23 CHMP opinion expected Q3 08, final decision anticipated Q4 08 (8) 09/04/2008 12:45:47 Confirmed plans to file in EU and expect to receive approval in 2007(1). Orphan drug status in EU and US (1). Plans to file in US in 06 (2). Filed in US Oct 06 (3). The FDA and the EMEA have designated Orphan Drug status to Junovan (3). Filed in EU Nov 06 (4). Negative opinion from FDA advisory committee May 07 (5). Non-approvable letter from FDA - more data required Aug 08 (6). 28/02/2008 09:51:04 Confirmed plans to file in EU and expect to receive approval in 2007(1). Orphan drug status in EU and US (1). Plans to file in US in 06 (2). Filed in US Oct 06 (3). The FDA and the EMEA have designated Orphan Drug status to Junovan (3). Filed in EU Nov 06 (4). Negative opinion from FDA advisory committee May 07 (5). Non-approvable letter from FDA - more data required Aug 08 (6). Company Information Name: Takeda US Name: IDM Pharma NICE Information In timetable: Yes When: Nov / 2010 Note: 17th wave, STA Prescribing Outlook: Available only to registered users Trial or other data Jul 10: in its draft guidance on mifamurtide, NICE has recommended against its use in combination with postoperative multi-agent chemotherapy in children, adolescents & young adults for treating high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection (14). 13/07/2010 09:49:30 Mar09: EU approval based on the Phase 3 MEPACT trial (INT-0133), a National Cancer Institute funded cooperative group study conducted by the Children′s Oncology Group and the largest study ever completed in osteosarcoma, enrolling approximately 800 patients. The study evaluated patient outcomes with the addition of mifamurtide to three- or four-drug adjuvant chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide). Results demonstrated that mifamurtide resulted in approximately a 30% decrease in the risk of death with 78% of patients surviving after six years of follow-up.(10) 09/03/2009 19:25:29 Filed in US for use in the treatment of newly diagnosed resectable high grade osteosarcoma following surgical resection in combination with multiple agent chemotherapy. IDM requested that the FDA consider granting priority review status, which could shorten review time from the standard ten months to six months if granted. The FDA customarily accepts or refuses to file NDAs and designates review status within 60 days of filing(3). Evidence Based Evaluations SMC http://www.scottishmedicines.org/smc/7718.html |
7楼2011-01-01 22:49:10
8楼2014-11-16 21:37:54
